pde2a

PDE9-IN-(S)-C33 ((S)-C33) 是一种有效的选择性 PDE9 抑制剂 (IC50 = 11 nM)。 PDE9-IN-(S)-C33 可用于中枢神经系统疾病和糖尿病的相关研究。

PF-05180999 (PF-999) 是一种具有选择性和高效性的磷酸二酯酶 2A (PDE2A) 抑制剂，可在大鼠的情境恐惧条件反射模型中增强了长期记忆。

PDE5-IN-2 is a potent, highly selective, and orally active inhibitor of PDE5(IC50 of 0.31 nM)

PF-05085727 inhibits PDE2A >4,000-fold selectivity over PDE1 and PDE3-11. PF-05085727 is an effective, selective and brain penetrant inhibitor of cGMP-dependent PDE2A (IC50=2 nM) .

TAK-915 is a potent, selective, and brain-penetrant phosphodiesterase 2A (PDE2A) inhibitor (IC50: 0.61 nM) with >4100-fold selectivity for PDE2A over PDE1A.

Ayanin 是从Croton schiedeanus Schlecht 中分离得到的黄酮类物质。它是非选择性的磷酸二酯酶抑制剂，在呼吸道疾病中有研究的价值，如过敏性哮喘等。

PDE2A-IN-1 is a phosphodiesterase 2A (PDE2A) inhibitor with an IC 50 value of 1.3 nM.

PF-04822163 是一种强效的 PDE1 抑制剂，其 IC50 值为 0.0024 μM。

EHNA hydrochloride 是一个具有的环核苷酸磷酸二酯酶 2 (PDE2) 和腺苷脱氨酶 (ADA)抑制剂，具有抗癌活性，以治疗时间依赖性方式增加细胞内腺苷浓度。EHNA hydrochloride 抑制 PHA 和 NaI04 有丝分裂发生。

PDE2 PDE10-IN-1 is a inhibitor of phosphodiesterase 2 (PDE2) and PDE10(IC50s of 29 and 480 nM, respectively).

PDE1-IN-8 (Compound 3f) 是一种 PDE1 抑制剂，其 IC50 为 11 nM。PDE1-IN-8 抑制 cAMP 和 cGMP 信号通路，阻断细胞向肌成纤维细胞的分化和增殖，并在 Bleomycin 诱导的大鼠肺纤维化模型中展现出抗纤维化效果。

PDE10A inhibitor

PF-06815189 is a phosphodiesterase 2A inhibitor. PF-06815189 also has good selectivity over other phosphodiesterases with a 1000-fold margin (PDE5 2 selectivity: 2439 nM 0.4 nM).

PDE1-IN-4 是有效的、选择性的 PDE1 (磷酸二酯酶 -1) 抑制剂，能够作用于 PDE1C (IC50: 10 nM)、PDE1A (IC50: 145 nM) 和 PDE1B (IC50: 354 nM)。PDE1-IN-4 能够调控 cAMP (3′,5′- 环磷酸腺苷) 和 cGMP (3′,5′- 环磷酸鸟苷)，表现出抗纤维化效果。PDE1-IN-4 能够抑制 TGF-β1 诱导的人肺成纤维细胞分化。PDE1-IN-4 能够用于研究特发性肺纤维化 (IPF)。

CP 461 (UNII-68OJX9I7DT) 是一种特异性 PDE2A 抑制剂，是一种新型促凋亡化合物，能抑制环 GMP 磷酸二酯酶，但不能抑制环氧化酶-1 或-2。CP 461 在体外可抑制多种人类肿瘤细胞系的生长，并选择性地诱导癌细胞系而不是正常细胞凋亡。

CP-461 (OSI-461) is a pde2a 5A inhibitor, which may be used in the treatment of renal cell carcinoma, prostate cancer, and Crohn's disease.

Hcyb1 is a potent and specific inhibitor of phosphodiesterase 2 (PDE2). It exhibits a high degree of selectivity for inhibiting PDE2A with an IC50 value of 0.57 μM. In addition, Hcyb1 displays over 250-fold selectivity against other recombinant members of the PDE family. Moreover, its pharmacological actions include neuroprotective and antidepressant-like effects, which are believed to be mediated through the cAMP cGMP-CREB-BDNF signaling pathway [1].